Shared in the colorectal universe
Jesus, thank you for another day and my life with this illness, please help me to help others and hopefully save a few lives including my own. Please look after Ren, Ted, Silvia, Peter and myself and all more cancer friends and friends without cancer. please keep them free of this challenge.
recurrence 2 day 4
http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=42296http://csn.cancer.org/node/259103
Dwight mkgee, an integrativ oncologist with vision. at last, we need another 100,000 dwights.
i read his journal, i could not agree more, so well said. at last, if you like his principles then just jump on a plane to germany and do medicine, not whats offered outside of germany. message me if you want details.
http://www.colonchat.net/forum/viewtopic.php?f=1&t=934&p=2565#p2565 a great post on colonchat, truly life saving ino there!
jim and lara,
dwight is the best onc in the states i have ever read about, at last some hope.
now we just need to clone him.
i suggest we print the article, give it to our oncs and say, have a read.
there opinion will be interesting to say the least, spend your money wisely i say.
i know onc in germany that practice based on dwights approaches but with access to state of the art vaccine and virus and antibodies.
but at last some hope for my american friends.
hugs,
pete
you may ask , what personalised transaltion oncology ?
see answer below, i added the work personalised to focus on the individual genetic and personalised clinical focus we all deserve as cancer patients.
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumor cells, to the most advanced clinical assays of Conventional and new drugs. In addition, the journal has a strong commitment to Facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of Tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, wants to be Considered for publication.
I expect the site to focus on a few detailed case studies showing the results of the intelligent combination of surgery, chemotherapy, immunotherapy and functional and integrative medicine. just because i dont post much here, does not mean i am not trying to find a durable robust set of therapies with curative potential for stage 4 who are deemed inoperable.
I have dropped basically my research into supplements and diets and am leaving that to a few good friends, i am focused on tuning and tweaking my immune system and finding the reason why recurrence 2 occured in the presence of dendtretic vaccinne 4 ? we already suspect we know why it failed, its not the science but the clincial management.
if anyone wants to help me run a professional website dedicated to the above, pm me. my web presentation skills leave alot to be desired.
The link above is a heroes story, Ted jumped into the unknown, i pray he is successful.
i a likely starting xeloda also, i pray you get the best result.
its a big step leaving your counties medical system, soon i pray we get these therapies for our other friends needing them.
the future is called personalised translation oncology, it will change the cancer world and save many of us.
you and your family are in my prayers, your success being watched by 100s, welcome to the trailblazers. i was so nice meeting you.
i am in the infusion room now. getting hammered as i am goung home to sydney in a month.
hugs,
pete
most western countries need / require clinical trials to prove effaciousy of therapies.
alas we are now in an era where the limitations of stadnardised medicine, one size fits all is clear to many, especially patients.
I am confident Ted, Ren and I and so many others will get great results, i have faith is these therapies despite my current chllenge small recurrence number 2.
the trailblazers will kick down the doors of conventional oncology, i think in a few weeks after asco, immunotherapy will be imprinted on the cancer landscape.
how long before vaccines are available for you ? i dont know, alot, a mountain, say as big as everest in work has to be done.
assessing imunocompetance, managing treg/msdc etc etc, genetically profiling tumours, changing surgical practices to be immuno friendly , these will all happen. watch my blog and my new website
i just registered another domain name personalisedtranslationaloncology , as long as i live I fight to make sure these therapies are available to all who want to have a go.
i thinks ted onc is supportive, my onc is supportive, he is going to be so happy to finally get some chemo into my viens. but does 500mg xeloda for breaky and dinner count.
hugs,
pete
Ghrelin and melatonin in the regulation of pancreatic exocrine secretion and maintaining of integrity.
Source
Department of Medical Physiology, Faculty of Health Care, Jagiellonian University Medical College, Cracow, Poland. mpjawore@cyf-kr.edu.pl
Abstract
Ghrelin and melatonin are produced in the central nervous system and in the gastrointestinal tissues; ghrelin in the stomach, and melatonin - in the liver and in the intestine. Both ghrelin and melatonin have been reported to protect the gastric mucosa against acute lesions and to influence gastrointestinal motility and secretions, however the physiological significance of these peptides in the gastrointestinal tissues remains unknown. In spite of the presence of ghrelin and melatonin receptors in the pancreatic tissue little is known about the role of these peptides in the pancreas. It is very likely that both ghrelin and melatonin, which are released from the gastrointestinal tract in relation to food ingestion, could be implicated in the postprandial stimulation of pancreatic enzyme secretion though the activation of cholinergic entero-pancreatic reflex and CCK release. Our experimental studies have shown that exogenous melatonin, as well as this produced endogenously from its precursor; L-tryptophan, strongly stimulates pancreatic amylase secretion when given intraperitoneally, or into the gut lumen. Intraduodenal administration of ghrelin also increases pancreatic enzyme secretion. This was accompanied by significant increases of CCK plasma levels. Above pancreatostimulatory effects of luminal administration of melatonin or ghrelin were completely reversed by bilateral vagotomy, capsaicin deactivation of sensory nerves or pretreatment of the rats with CCK1 receptor antagonist; tarazepide. Our previous findings have revealed that melatonin, as well as its precursor; L-tryptophan, effectively protects the pancreas against the damage induced by caerulein overstimulation. The beneficial effects of melatonin and L-tryptophan on the pancreas have been related to the ability of melatonin to scavenge the radical oxygen species (ROS), to activate antioxidative enzymes and to modulate the cytokine production. It has been previously shown that systemic application of ghrelin attenuated acute pancreatitis activating the immune defense mechanisms. Our recent data demonstrate that ghrelin is able to prevent pancreatic inflammatory damage though the activation of central nervous mechanisms leading to the improvement of antioxidative properties of pancreatic tissue. The results of experimental studies indicated that melatonin and ghrelin could take a part in the protection of pancreatic tissue against the damage under physiological conditions.
http://www.hindawi.com/journals/jo/2012/281261/ why celebrex
Metabolic products of cyclooxygenase 2 (COX2), prostaglandins in particular, contribute to neovascularisation and support vasculature-dependent growth of CRC, invasion, and metastasis [31, 61,62]. COX2 is upregulated in approximately 50% of adenomas and 85% of adenocarcinomas [63, 64] and associated with worse survival among CRC patients [65]. Genetic deletion of COX2 dramatically reduces intestinal polyp formation supporting a key function of COX2 in CRC tumorigenesis [66]. Functionally, COX2 triggers secretion of MMP2 and MMP9 and enhances the expression of proangiogenic growth factors including VEGF and bFGF. It therefore contributes to the dissolution of the collagen matrix, EC migration, and formation of tubular networks [67–70]. COX2 inhibitors suppress VEGF and bFGF expression and thereby block angiogenesis [71–73]. Indeed, both aspirin and nonaspirin-NSAIDs given daily reduce the incidence of CRC significantly [74, 75].
Re: T3cN2a, refusing chemotherapy?
by pete43lost_at_sea » Sat May 18, 2013 7:46 pm- pete43lost_at_sea
- Posts: 34
- Joined: Tue Mar 29, 2011 6:26 am
http://www.colonchat.net/forum/viewtopic.php?f=1&t=904&p=2566#p2566 NDV old good news.
its tumout lysis syndrome, i suggest a few rounds of chemo to shrink tumours safely, or have them embolised, then hit them with super effectiv immunotherapies.
to role of msdc and treg i think is supposed to rate limit these leafal side effects. as we inhitib these immune modulators we are opening a can of worms. if you are interested, ask me about my friends rat die died from coleys induced tumour lysis syndrome.
hugs,
to role of msdc and treg i think is supposed to rate limit these leafal side effects. as we inhitib these immune modulators we are opening a can of worms. if you are interested, ask me about my friends rat die died from coleys induced tumour lysis syndrome.
hugs,
pete